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Purpose: Current strategies to create small-diameter vascular grafts involve seeding biocompatible, compliant scaffolds
with autologous vascular cells. Our purpose was to study the composition and strength of decellularized vein to determine
its potential as a vascular tissue-engineering scaffold.
Methods: Intact human greater saphenous vein specimens were decellularized by using sodium dodecyl sulfate (SDS).
Residual cellular and extracellular matrix composition was studied with light and electron microscopy as well as
immunohistochemistry. Burst and suture-holding strength was measured in vitro by insufflation and pull-through
techniques. To assess initial handling and durability of decellularized vein in vivo, a canine model was developed wherein
decellularized canine jugular veins were implanted as carotid interposition grafts in recipient animals. After two weeks of
arterial perfusion, these grafts were studied with duplex imaging and histologic methods.
Results: Human saphenous vein decellularized by using SDS was devoid of endothelial cells and >94% of the cells resident
within the vein wall. Collagen morphology appeared unchanged, and elastin staining decreased only slightly. Basement
membrane collagen type IV remained intact. Compared with fresh vein, decellularized vein had similar in vitro burst
(2480  460 mm Hg vs 2380  620 mm Hg; P > .05) and suture-holding (185  30 gm vs 178  66 gm; P > .05)
strength. Decellularized canine vein functioned well in vivo without dilation, anastomotic complication, or rupture over
2 weeks of arterial perfusion.
Conclusions: Vein rendered acellular with SDS has well-preserved extracellular matrix, basement membrane structure, and
strength sufficient for vascular grafting. These properties suggest proof of concept for its use as a scaffold for further
vascular tissue engineering. (J Vasc Surg 2004;40:146-53.)
Clinical Relevance: The following research examines the creation of a new small-diameter bypass graft.
It is clinically relevant to patients who need distal arterial bypass, coronary artery bypass, or hemodialysis access, but who
do not have adequate autologous vein for their surgeries. Future investigations will involve further tissue engineering of
this vascular scaffold (eg, autologous endothelial seeding of its lumen) and testing the clinical usefulness of the completed
graft.Autologous vascular tissue remains the standard for
small-diameter (6-mm) arterial bypass. For patients who
lack this tissue vital for successful surgery, the currently
available prosthetic, biologic, and allograft alternatives are
less than satisfactory. Early tissue-engineering strategies to
solve this problem involved seeding nonabsorbable pros-
thetic grafts with vascular cells.1,2 Although these conduits
have shown promise, they have not achieved widespread
clinical acceptance. More recent techniques involve seeding
of biocompatible, compliant scaffolds with vascular cells.
Examples include tubes made of collagen, biodegradable
polymers, and xenograft arterial tissue rendered acellular by
using aldehyde fixation or other various cell extraction
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but remain challenged with issues such as adequate initial
strength, cell viability following polymer degradation, im-
munologic incompatibility, and long-term aneurysm for-
mation.
The present study investigates an alternative scaffold
for vascular tissue engineering. This scaffold is created by
treating human saphenous vein derived from transplant
tissue donors with a detergent (sodium dodecyl sulfate
[SDS]) to remove its cells, thereby decreasing its antigenic-
ity. The use of human vein as a tissue source for vascular
scaffold creation has not been well described in the litera-
ture. Potential advantages to its use include ready availabil-
ity, ease of procurement from transplant tissue donors, and
the avoidance of significant immunogenic issues associated
with xenograft tissues. Furthermore, the use of SDS to
decellularize venous tissue has not been previously re-
ported. Possible advantages to its use include preservation
of extracellular matrix important for strength and cell at-
tachment, and avoidance of problems associated with alde-
hyde-fixed tissues (poor graft compliance and aneurysmal
degeneration).
Of all these potential advantages, the most important
characteristic of this or any new vascular conduit is ade-
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devastating complications of acute rupture and anasto-
motic degeneration. Herein, we investigate the composi-
tion and structure of SDS-decellularized vein and test the
hypothesis that it retains the structural integrity necessary
to withstand arterial implantation.
MATERIAL AND METHODS
This study was conducted under protocols approved by
Thomas Jefferson University’s Institutional Review Board
and Institutional Animal Care and Use Committee. The
animal care complied with the Guide for the Care and Use of
Laboratory Animals. Table I summarizes the materials and
methods used in this study.
Vein preparation. Human greater saphenous vein
(GSV), taken from all segments of the lower extremity, was
obtained fresh from patients undergoing vascular surgical
procedures. To avoid bias based on vein caliber or location,
only specimens long enough to be cut into adjacent control
and experimental samples were used. The nondistended
segments were transported to the laboratory in Medium
199 (Gibco BRL, Grand Island, NY) at 4°C. Decellulariza-
tion was performed by placing the specimens in SDS
(Sigma Chemical Company, St. Louis, Mo) in a 37oC
shaking water bath for 15 hours. The veins were subse-
quently washed with agitation 5 times in phosphate-buff-
ered saline (PBS) for periods of 10 minutes each. To
determine the minimal concentration of SDS necessary to
achieve decellularization, concentrations of 0.01, 0.025,
0.05, 0.075, and 0.1% SDS in PBS were tested. Controls
included untreated freshly harvested vein, as well as vein
processed similar to treated veins but without SDS (0.0%
SDS).
Determination of cellularity. One-cm vein segments
were fixed in 10% formalin, paraffin embedded, transversely
sectioned (5 m) at their midpoints, and stained with
hematoxylin-eosin. By using a light microscope interfaced
with an image analysis system (Phase 3 Imaging System and
Spot RT true color digital camera), all nuclei in the intima,
Table I. Summary of materials and methods*
Characteristic Method
Cellularity
ECs LM, SEM H
Transmural LM H
ECM
Collagen, elastin LM H
Basement membrane Immunohistochemistry H
In vitro mechanical strength Burst strength H
Suture pull-through H
In vivo durability Duplex ultrasound C
Pathologic examination C
EC, Endothelial cells; LM, light microscopy; SEM, scanning electron m
extracellular matrix; EJV, external jugular vein.
*The plan used to characterize the structure and strength properties of decmedia and adventitia present within a 0.025-mm band-
width were counted. Four quadrants in 4 transverse sec-
tions (total of 16 counts) were averaged for each fresh
control (n  10) and decellularized (n  10) specimen.
% decellularization [cell count for fresh vein cell count
for decellularized vein] cell count for fresh vein 100%.
Vein submitted for scanning electron microscopy was
fixed overnight by using 2.5% glutaraldehyde in cacodylate
buffer at 4oC. Samples were then post-fixed in 1% OsO4,
and dehydrated with graded ethanol. The specimens were
then critical-point dried, opened longitudinally, mounted
lumen side up, and sputter-coated with gold. Specimens
were then viewed using a JEOL 840 scanning electron
microscope. The luminal surface of 4 fresh control and 4
decellularized (0.075% SDS) veins were examined qualita-
tively for the presence of endothelial cells (ECs).
Evaluation of extracellular matrix. Collagen and
elastin morphology was analyzed, using methods similar to
Har-Shai et al.16 Vein samples were fixed in 10% formalin,
paraffin embedded, sectioned transversely (5 m) and dou-
ble-stained by using the Verhoff-vonGieson method. Us-
ing a light microscope interfaced with a digital image
analysis system, the area occupied by both collagen (red)
and elastin (black) fibers17 per high-powered field (hpf 
40magnification) was measured. Twenty areas in 4 trans-
verse sections (total of 80 hpf) were averaged for each fresh
control (n  10) and decellularized (n  10) specimen.
Percent fiber  [average fiber area per hpf]  100%.
Basement membrane was evaluated by using immuno-
histochemistry. Paraffin-embedded blocks containing vein
specimens fixed in 10% formalin were deparaffinized and
rehydrated in ethanol followed by water. After blocking
sections with H2O2, mouse IgG monoclonal antibody
against the 7S domain of human type IV collagen (Chemi-
con, Temecula, Calif) was applied and incubated for 1 hour
using a 1:5,000 dilution. The immune complexes were
then visualized by light microscopy following application of
Dako Liquid DAB Substrate-Chromogen Solution
(DakoCytomation, Carpinteria, Calif) and counterstaining
Vein
Controlsurce n
Minimal segment
length (cm)
n GSV 10, 4 1 0% SDS
n GSV 10
n GSV 10 1 Fresh GSV
n GSV 4
n GSV 10 2.5 Fresh GSV
n GSV
e EJV 4 4 Autograft (–),
Allograft ()e EJV
opy; GSV, greater saphenous vein; SDS, sodium dodecyl sulfate; ECM,
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uma
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uma
anin
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larized vein samples were submitted for immunohisto-
chemical analysis.
Assessment of mechanical graft strength in vitro.
Burst and suture-holding strength was tested by using
methods similar to Smitten.18 For burst strength, vein
specimens (2.5 cm) were cannulated proximally, filled with
PBS, and occluded distally with a silk tie. Intraluminal
pressure was increased by 300mm Hg/s using an ACS
Indeflator Plus 20 pressure gauge until vein rupture. Burst
strength was recorded in mm Hg for both fresh control
(n  10) and decellularized (n  10) specimens.
Suture-holding strength was measured by using a
spring-loaded tensiometer. Polypropylene sutures (5-0)
were placed in 4 quadrants 1 mm from the vessel edge.
Increasing linear pressure was increased by 50gm/s until
the suture pulled through the vein edge. Eight measure-
ments (4 values taken from both ends of the vein sample)
were averaged for fresh control (n 10) and decellularized
(n  10) veins, and recorded in grams.
Assessment of graft durability in vivo. To evaluate
the strength of decellularized vein in vivo, a canine vein
graft model mimicking human arterial bypass grafting was
developed. Preliminary experiments identical to those used
to determine the cellularity of human vein after SDS treat-
ment were performed with canine external jugular vein.
Transmural cell removal was again near complete using
0.075% SDS.
Using 1-year-old, 25- to 30-kg female mongrel dogs
(n  8), 16 external jugular vein grafts were harvested and
prepared as follows: (1) autografts (n  8) were immedi-
ately placed back into the donor animal, (2) allografts (n
4) were immediately transplanted into a recipient animal,
and (3) decellularized allografts (n  4) underwent cell
extraction by using 0.075% SDS prior to transplantation
into a recipient animal. These veins were implanted bilat-
erally as carotid interposition grafts as follows: after hepa-
rinization (3000 U), the vein grafts (4 cm) were reversed,
spatulated, and sutured using 7-0 polypropylene, with ex-
cision of the intervening carotid artery. Each animal re-
ceived a fresh autograft plus either a fresh allograft or
decellularized allograft on the contralateral side. Electronic
calipers were used to measure midgraft diameter immedi-
ately following reperfusion. The heparin was reversed with
protamine, and the animal was recovered. No aspirin was
administered.
Table II. Decellularization of human greater saphenous ve
Fresh vein 0.00
# of nuclei w/in 0.025mm bandwidth 42  11 27  1
% Decellularization 35
Values represent the mean  SD (n  10).
SDS, Sodium dodecyl sulfate.
*P  .001 compared with fresh vein.At two weeks, all grafts underwent transcutaneous du-
plex Doppler ultrasound examination using high frequency
linear array transducers (Siemens Medical Systems, Acuson
Sequoia 512) to assess patency, dilation (largest graft diam-
eter was measured in mm) and anastomotic false aneurysm
formation. The grafts were subsequently explanted under
general anesthesia. The carotid arteries were cannulated
proximally and distally to the interposition graft and perfu-
sion-fixed with 500 cc of 10% buffered formalin at 100 mm
Hg over 30 minutes. The grafts were explanted en bloc,
fixed for an additional 24 hours, and sectioned. The sec-
tions were paraffin embedded, hematoxylin-eosin stained,
and examined with light microscopy.
Statistical analysis. All data are reported as average
value  standard deviation. Paired, two-tailed Student t
tests were performed to determine if the cell counts, fiber
areas, and burst and suture-holding strengths were statisti-
cally different (P  .05) between the groups tested.
RESULTS
Decellularization of vein by SDS is nearly complete.
Both light (Fig 1) and scanning electron (Fig 2) micros-
copy revealed that the luminal surface of human GSV is
completely devoid of endothelial cells following treatment
with SDS. This was observed at all concentrations of SDS
tested (0.01%-0.1%). Examination of transverse vein sec-
tions further revealed that SDS removed cells resident
within the vein wall. Table II shows quantification of cell
extraction for the entire vessel wall versus SDS concentra-
tion used. Cell removal was significant for all treatment
groups (P  .001) and was concentration-related, with
near total decellularization (	94%) occurring at SDS con-
centrations 0.075%. As decellularization was essentially
complete following 0.075% SDS treatment, this concentra-
tion was used for all further morphologic and strength
studies.
Extracellular matrix structure is preserved follow-
ing decellularization. Light microscopy (Fig 3) of fresh
and SDS-treated vein stained with the Verhoff-vonGieson
method revealed gross preservation of extracellular matrix
collagen and elastin fibers. Digital image analysis of fresh
and decellularized specimens (Fig 4) suggested that colla-
gen fiber area remained stable (45.8%  4.6% vs 41.5% 
7.3%; P	 .05) and elastin fiber area decreased only slightly
(10.4 4.8 vs 8.3%  3.8%; P  .02).
ter treatment with increasing concentrations of SDS
SDS used to decellularize vein
0.01% 0.025% 0.05% 0.075% 0.1%
29  8* 20  8* 15  11* 3  4* 2  2*
32 52 64 94 96in af
%
1*
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(Fig 5), the major component of vascular basement mem-
brane, revealed preservation of this protein after SDS cel-
lular extraction. Qualitatively, a dense layer of collagen IV is
seen along the luminal surface and within the vessel wall of
both the fresh and SDS-treated veins.
Fig 1. Light micrograph of human greater saphenous v
(hematoxylin-eosin stain, 20 original magnification). SD
(arrow) and 	94% of the cells within the vessel wall.
Fig 2. Scanning electron micrograph of luminal surface o
treatment with 0.075% SDS (500). Endothelial cells
where only basement membrane is seen.Decellularized vein is mechanically strong. In vitro
study revealed that burst (2480 470 vs 2380 620 mm
Hg, respectively; P	 .05) and suture-holding (185 30 vs
178  66 gm; P 	 .05) strength was not significantly
altered following cellular extraction with 0.075% SDS (Fig
6). Grossly, decellularized vein appeared pale, with other-
fore (left) and after (right) treatment with 0.075% SDS
atment completely removes the luminal endothelial cells
an greater saphenous vein before (left) and after (right)
on the left (arrow) are completely absent on the right,ein be
S tref hum
seen
D (n
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to fresh vein.
Decellularized vein remains stable following im-
plantation into the arterial system. In vivo canine
experiments revealed that decellularized vein grafts had
operative handling characteristics indistinguishable from
fresh vein grafts. Intraoperative hemostasis was achieved
Fig 3. Light micrograph of human greater saphenous v
(Verhoff-vonGieson stain, 40 original magnification)
elastin (black fibers, arrowheads) morphology.
Fig 4. Quantification of area occupied by collagen (lef
before and after treatment with 0.075% SDS, suggesti
content. Values represent average fiber area per hpf  Swith equal success in both decellularized and fresh vein
groups.
All animals survived surgery and the 2 weeks follow-
ing implantation without neurologic, infectious, or hem-
orrhagic complication. All grafts remained patent by
both duplex and pathologic examination. No significant
graft dilation (Table III), rupture or anastomotic false
fore (left) and after (right) treatment with 0.075% SDS
ling preservation of collagen (pink fibers, arrows) and
elastin (right) fibers in human greater saphenous vein
eservation of collagen and a slight decrease in elastin
 10); *P  .02 compared with fresh vein.ein be
reveat) and
ng pr
SD (n
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perfusion.
DISCUSSION
This study represents our initial efforts to tissue engi-
neer a small-diameter bypass graft. Similar to other engi-
Fig 5. Basement membrane architecture of human great
0.075% SDS (200). Immunohistochemistry using m
basement membrane brown, and reveals preservation o
surrounding the areas formally occupied by the smooth
Fig 6. In vitro strength studies measuring both burst p
greater saphenous vein before and after cell extraction wit
following decellularization. Values represent average neering paradigms, our ultimate goal is to develop an
“off-the-shelf” conduit-scaffold that subsequently can be
seeded with autologous vascular cells prior to implantation.
We chose human GSV as the tissue source for such a
product. In practice, this vein would be harvested from
transplant tissue donors, decellularized to reduce antigenic-
henous vein before (left) and after (right) treatment with
lonal antibody to human collagen Type IV stains the
s protein along the luminal surface (arrow) as well as
le cells (arrowhead).
re (left) and suture-holding (right) strength in human
75% SDS. No significant alteration in strength was noted
 10).er sap
onoc
f thi
muscressu
h 0.0
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seeding and use.
In these beginning investigations, we developed a tech-
nique for decellularizing venous tissue using SDS, a com-
mon tissue detergent. Using the minimal SDS concentra-
tion necessary to render vein acellular, we subsequently
demonstrated retention of extracellular matrix morphology
and strength. Together, these studies serve as proof of
concept for the use of decellularized vein as potential a
conduit-scaffold for vascular tissue engineering.
Although many recent vascular tissue engineering strat-
egies use artery as a tissue source, use of human saphenous
vein offers several potential advantages: (1) ease of harvest
from transplant tissue donors, (2) length and diameter
appropriate for bypass procedures, (3) a thin vascular wall
that is easy to decellularize, and (4) a thinner matrix that
allows for migration of autologous recipient cells and im-
proved luminal inspissation of nutrients. Of note, several
investigators use xenograft vascular sources for ready avail-
ability. Use of allograft tissue, however, avoids various
infection issues as well as the known propensity for xeno-
graft vascular tissue to degenerate into aneurysm.19,20
Decellularization is a technique used to decrease anti-
genicity, thereby reducing subsequent graft rejection and
host allosensitization. There are several methods to remove
cells from tissue; these include hypotonic cell lysis, enzy-
matic digestion, mechanical stripping, and tissue fixation.
SDS is a tissue detergent that lyses cell membranes, and is
one of many such detergents. We have chosen SDS for
study because of its (1) ease of use, (2) success in a pub-
lished model of vascular tissue decellularization,19,20 and
(3) ability to lyse cells uniformly within all layers of the
tissue. Furthermore, its mechanism of action may make it
less damaging than other enzymatic, mechanical, or tissue
fixation methods. A major goal of this study is to examine
the effect of SDS on venous tissue, a process unreported in
the literature.
Decellularization with SDS resulted in uniform cell
removal throughout the tissue. Complete endothelial cell
removal was not surprising, even for the lowest SDS con-
centrations, as their loss is also promoted by tissue hypoxia
and mechanical shaking. Removal of the smooth muscle
Table III. Vein graft diameter before and 2 weeks after
implantation into arterial circulation as a carotid
interposition graft in a canine in vivo model
Vein group
Vein graft diameter (mm)
Initial 2 wk
Autografts 7.5  1.1 8.5  1.6
Allografts 7.7  1.1 7.0  1.6
Decellularized allografts 7.3  0.6 7.7  1.0
Initial graft diameter measured by calipers immediately after reperfusion at
time of implantation; 2-week diameter is based on surface duplex measure-
ment; values represent mean SD (n 8 for group 1; n 4 for both groups
2 and 3).cells required higher concentrations of SDS, and appeared
dose-related.
Examination of the extracellular matrix and basement
membrane demonstrated that SDS did not significantly
alter morphology. This finding is important as collagen is
responsible for vessel strength, and elastin imparts disten-
sibility and recoil.21 Additionally, as type IV collagen con-
tains ligands important for firm endothelial cell attachment
and retention, basement membrane preservation may be
key to foster the future repopulation of these grafts with
vascular cells.22
Adequate initial strength is an absolute requirement for
any arterial bypass graft. A primary goal of this study was to
determine the strength of SDS-treated vein and its feasibil-
ity as a vascular conduit. Results of the in vitro strength tests
(burst and suture pull-through) suggest that SDS decellu-
larization did not significantly alter vein strength. From a
functional standpoint, this finding corroborates our find-
ings that no significant change was found in collagen mor-
phology.
To further substantiate these in vitro findings, we de-
veloped an in vivo canine model that mimics the use of
decellularized vein in humans. In this model, canine exter-
nal jugular vein was used as a tissue source for decellularized
vein grafts. By preserving this allogenic relationship be-
tween the donor grafts and recipients, we avoided the
immunologic issues with xenograft transplantation. These
in vivo studies demonstrated excellent handling character-
istics of decellularized vein grafts and their ability to with-
stand arterial pressure without vascular complication over a
2-week period. Combined with the in vitro studies, these
results provide the strongest proof of concept and safety for
the potential use of decellularized vein as a bypass graft.
In addition to conduit strength, an equally important
characteristic of arterial bypass is maintenance of patency.
The in vivo model used in this study (a high-flow, large-
diameter site) was chosen because it tests the graft’s ability
to withstand arterial pressure without the confounding
factor of thrombosis.23 As such, we cannot draw significant
conclusion about this important characteristic. Given the
pivotal role endothelial cells play in maintaining patency
under low-flow conditions, we suspect decellularized vein
would not perform equally to autologous tissues in these
circumstances. Luminal seeding of the graft with autolo-
gous endothelial cells prior to implantation is now the
subject of ongoing studies.
Study limitations. The mainstay of our structural
analysis was digital image analysis following histochemical
staining. Although our methods suggest stable extracellular
matrix fiber morphology, quantitative molecular analysis of
collagen and elastin was not performed to assay structural
changes within the fibers themselves. Similarly, although
our techniques to measure in vitro and in vivo strength and
handling provided reliable data consistent with values
found in the literature for fresh saphenous vein,18 they may
not be definitive predictors of long-term durability. This
latter characteristic is dependent upon many factors, in-
cluding extracellular matrix production and turnover. Fi-
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nous vein cannot directly be assured by the results of our
animal model. Because we chose to use canine vein as the
tissue source for our grafts, thereby avoiding the confound-
ing immunogenic issues of putting human vein directly into
the model, the structural differences between human sa-
phenous vein and canine jugular vein weakens our
conclusions.
SUMMARY
These data suggest that vein decellularized by using
SDS represents a potential scaffold for further vascular
tissue engineering efforts. Cell extraction by using SDS is
simple and near complete, without significant disturbance
of the extracellular matrix and basement membrane mor-
phology. Excellent strength was demonstrated in both in
vitro and in vivo studies, attesting to the preservation of its
basic extracellular matrix structure.
We are grateful to Yi Shi, MD, PhD, of the Department
of Surgery for reviewing the manuscript; David Kreitzer
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scanning electron microscopy; and Daniel Merton, BS,
RDMS and Kathryn James, MBA, RDMS, from the De-
partment of Radiology for performing the carotid duplex
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